Lack of Important ‘Gatekeeper’ Protein Linked to Skin Cancer

	Tweet

New research from North Carolina State University shows that a “gatekeeper” protein plays an important role in skin-cancer prevention in humans and lab mice.

The protein, C/EBP alpha, is normally abundantly expressed to help protect skin cells from DNA damage when humans are exposed to sunlight. The NC State research shows, however, that the protein is not expressed when certain human skin cancers are present.

Moreover, when the protein is inactivated in special lab mice exposed to small amounts of the UVB solar radiation, the mice become more susceptible to skin cancer.

Dr. Robert Smart, professor of environmental and molecular toxicology at NC State and the corresponding author of a paper in the Journal of Investigative Dermatology describing the research, says that C/EBP alpha serves as an important “pause button” in cells. If there is any DNA damage, C/EBP alpha halts the cell-replication process to allow time for cells to repair themselves to prevent DNA errors from occurring.

“Loss of C/EBP alpha expression is associated with some of the most common human cancers, including breast and colon cancer,” Smart says. “We think it may also have a role in tumor suppression in these cancers via its gatekeeper function.”

In the study, the researchers found that human skin expresses C/EBP alpha as does the pre-cancerous, benign lesion called actinic keratose – the precursor to skin cancer.

“C/EBP alpha is expressed in normal human skin and in pre-cancerous actinic keratoses, but something happens when cancerous lesions appear – the protein is not expressed,” Smart says. “We then asked, ‘Is the loss of C/EBP alpha contributing to tumor formation?’ The answer seems to be yes.”

Smart and colleagues exposed hairless, genetically modified mice – bred with C/EBP alpha inactivated – to low doses of the UVB solar radiation. The mice were highly susceptible to certain common types of skin cancer – squamous cell carcinomas – with these cancerous tumors developing and growing rapidly.

“If you can figure out how to keep C/EBP alpha turned on, maybe the tumor would stay in its pre-cancerous state,” Smart says.

Smart adds that figuring out how the protein fulfills its gatekeeper role – and how and why the protein is inactivated in cancerous cells – marks the next step in his research.

The research was funded by the National Institute of Environmental Health Sciences and the National Cancer Institute. Colleagues from the University of Chicago and Columbia University contributed to the study, as did graduate students and postdocs in Smart’s laboratory.

- kulikowski -

Note: An abstract of the paper follows.

“C/EBP alpha Expression is Downregulated in Human Nonmelanoma Skin Cancers and Inactivation of C/EBP alpha Confers Susceptibility to UVB-Induced Skin Squamous Cell Carcinomas”

Authors: Elizabeth A. Thompson, Songyun Zhu, Jonathan R. Hall, John S. Hoose, Rakesh Ranjan, Jeanne A. Burr and Robert C. Smart, North Carolina State University; Yu-Ying He, University of Chicago; David M. Owens, Columbia University

Published: June 2011 print edition of Journal of Investigative Dermatology

Abstract: Human epidermis is routinely subjected to DNA damage induced by UVB solar radiation. Cell culture studies have revealed an unexpected role for C/EBP alpha (CCAAT/enhancer-binding protein-alpha) in the DNA damage response network, where C/EBP alpha is induced following UVB DNA damage, regulates the G1 checkpoint, and diminished or ablated expression of C/EBP alpha results in G1 checkpoint failure. In the current study we observed that C/EBP alpha is induced in normal human epidermal keratinocytes and in the epidermis of human subjects exposed to UVB radiation. The analysis of human skin precancerous and cancerous lesions (47 cases) for C/EBP alpha expression was conducted. Actinic keratoses, a precancerous benign skin growth and precursor to squamous cell carcinoma (SCC), expressed levels of C/EBP alpha similar to normal epidermis. Strikingly, all invasive SCCs no longer expressed detectable levels of C/EBP alpha. To determine the significance of C/EBP alpha in UVB-induced skin cancer, SKH-1 mice lacking epidermal C/EBP alpha (CKO alpha) were exposed to UVB. CKO alpha mice were highly susceptible to UVB-induced SCCs and exhibited accelerated tumor progression. CKO alpha mice displayed keratinocyte cell cycle checkpoint failure in vivo in response to UVB that was characterized by abnormal entry of keratinocytes into S phase. Our results demonstrate that C/EBP alpha is silenced in human SCC and loss of C/EBP alpha confers susceptibility to UVB-induced skin SCCs involving defective cell cycle arrest in response to UVB.

###

Mick Kulikowski | News Services | 919.515.8387
Dr. Robert Smart | 919.515.7245

RELATED STORIES:
Study reveals possible link between IBD therapy and skin cancer   Parents favor genetic testing for melanoma in their children   College athletes unconcerned about skin cancer   Photodynamic therapy lighting the way for medical treatments   Roche melanoma pill spurs growth of less harmful cancers   Women with melanoma fare better than men   Image Analysis Project Aims to Classify Characteristics of Skin Cancer   Peplin announces positive results of skin cancer trial   More Accurate Method Required for Tracking Skin Cancer Cases   Stop signal discovered for skin cancer   Discovery at JGH opens door to new treatments for prostate, brain and skin cancers   Hispanics and Blacks with Melanoma More Likely to Be Diagnosed at a Later Stage   IBD patients face increased skin cancer risk   Widely Used Arthritis Pill Protects Against Skin Cancer   Light, chemistry, action—a new technique to target skin cancers?   Skin cancer epidemic underway in the US   Skin cancer study uncovers new tumor suppressor gene   Potential Target for Skin Cancer Treatment   Melanoma overdiagnosed in US   Oklahoma doctors, cancer survivor warn of sun danger   Ultraviolet light helps skin cancer cells thrive, researchers report   Doctors may be able to hear skin cancer spread

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]